MX2013010910A - Peptidos neuroprotectores. - Google Patents

Peptidos neuroprotectores.

Info

Publication number
MX2013010910A
MX2013010910A MX2013010910A MX2013010910A MX2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A
Authority
MX
Mexico
Prior art keywords
acid sequence
amino acid
amino acids
cd44v10
neuroprotective peptides
Prior art date
Application number
MX2013010910A
Other languages
English (en)
Inventor
Elhanan Pinner
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of MX2013010910A publication Critical patent/MX2013010910A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un método para tratar un trastorno neurodegenerativo. El método comprende administrar al sujeto una cantidad terapéuticamente efectiva de un péptido aislado que comprende por lo menos 3 aminoácidos de una secuencia de aminoácidos CD44V10 y no más de 20 aminoácidos de la secuencia de aminoácidos CD44V10 y que comprende una actividad neuroprotectora.
MX2013010910A 2011-03-24 2012-03-22 Peptidos neuroprotectores. MX2013010910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466966P 2011-03-24 2011-03-24
PCT/IL2012/050104 WO2012127475A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Publications (1)

Publication Number Publication Date
MX2013010910A true MX2013010910A (es) 2014-03-27

Family

ID=45999925

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010910A MX2013010910A (es) 2011-03-24 2012-03-22 Peptidos neuroprotectores.

Country Status (13)

Country Link
US (1) US20140045764A1 (es)
EP (1) EP2688582B1 (es)
JP (1) JP5960793B2 (es)
KR (1) KR20140036164A (es)
CN (1) CN103648517B (es)
AU (1) AU2012232642B2 (es)
BR (1) BR112013024323A2 (es)
CA (1) CA2830792A1 (es)
EA (1) EA201391387A1 (es)
MX (1) MX2013010910A (es)
SG (1) SG193418A1 (es)
WO (1) WO2012127475A1 (es)
ZA (1) ZA201307169B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
WO2017131468A1 (ko) * 2016-01-27 2017-08-03 경상대학교산학협력단 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물
US10981956B2 (en) 2016-03-31 2021-04-20 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
US10660934B2 (en) 2016-03-31 2020-05-26 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
US20200347107A1 (en) 2017-11-14 2020-11-05 Senju Pharmaceutical Co., Ltd. Pacap stabilized peptide
JP7260930B2 (ja) 2018-11-08 2023-04-19 ニオバスク ティアラ インコーポレイテッド 経カテーテル僧帽弁人工補綴物の心室展開
EP3974027A4 (en) 2019-05-14 2023-08-16 Senju Pharmaceutical Co., Ltd. STABILIZED PACAP PEPTIDE
CN114173874A (zh) 2019-05-14 2022-03-11 千寿制药株式会社 含pacap肽或pacap的稳定化肽的神经营养性角膜炎的预防或治疗用组合物
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
WO1995019183A1 (en) * 1994-01-18 1995-07-20 President And Fellows Of Harvard College Cd44 expression in smooth muscle cells
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
AU3448899A (en) * 1998-01-24 1999-08-09 Bristol-Myers Squibb Company Artificial proteoglycans
DE602004027255D1 (de) * 2004-10-14 2010-07-01 Karlsruher Inst Technologie Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren
CA2692861A1 (en) * 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases

Also Published As

Publication number Publication date
CA2830792A1 (en) 2012-09-27
JP5960793B2 (ja) 2016-08-02
KR20140036164A (ko) 2014-03-25
CN103648517A (zh) 2014-03-19
JP2014510101A (ja) 2014-04-24
WO2012127475A1 (en) 2012-09-27
EP2688582A1 (en) 2014-01-29
EP2688582B1 (en) 2017-02-15
BR112013024323A2 (pt) 2017-06-13
AU2012232642B2 (en) 2016-12-08
AU2012232642A1 (en) 2013-10-17
CN103648517B (zh) 2016-04-20
SG193418A1 (en) 2013-10-30
EA201391387A1 (ru) 2014-01-30
ZA201307169B (en) 2014-05-28
US20140045764A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
MX2013010910A (es) Peptidos neuroprotectores.
AU2018253546A1 (en) Aromatic-cationic peptides and methods for using same
MX2022013517A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
EA202090053A2 (ru) Способы и композиции для лечения неэффективного эритропоэза
IN2014KN01713A (es)
IN2014KN01715A (es)
IN2014KN01716A (es)
IN2014KN01714A (es)
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
NZ601868A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2528934A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
IN2014CN04498A (es)
CA2889275C (en) Novel method for treating cardiac infarction using hmgb1 fragment
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
FI20115870A0 (fi) Neuroprotektiiviset soluihin tunkeutuvat peptidit
WO2014082042A3 (en) Peptides that stimulate subcutaneous adipogenesis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal